周五早盘，中国抗体-B（03681.HK）股价出现显著上涨，盘中涨幅达14.45%，引发市场关注。
据市场消息，医药股板块整体呈现强势上涨态势。其中，新上市的维立志博-B（09887.HK）首日挂牌表现亮眼，涨幅一度超过120%。除中国抗体-B外，樂普生物-B（02157.HK）上涨3%，同源康醫藥-B（02410.HK）上涨4%，显示医药板块整体受到资金青睐。
分析人士指出，维立志博-B的成功上市可能是推动医药股集体上涨的重要因素。该公司在公开发售阶段获得3494.78倍超额认购，国际配售阶段也获得40.78倍认购，反映出投资者对医药行业前景的乐观预期。这种积极情绪似乎已经扩散到整个医药板块，带动包括中国抗体-B在内的多只医药股价格上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.